XTX501 in Patients With Metastatic Non-Small Cell Lung Cancer and Advanced Solid Tumors

This is a first-in-human, multicenter, Phase 1/2, open-label study designed to evaluate the safety and tolerability of XTX501 as monotherapy in participants with metastatic non-small cell lung cancer (NSCLC) and select advanced solid tumors.

Trial Details

NCT ID
NCT07688577
Phase
PHASE1 / PHASE2
Sponsor
Xilio Development, Inc.
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • XTX501
Locations (sample)
  • Canton, Ohio, United States|40.79895,-81.37845
  • Fort Worth, Texas, United States|32.72541,-97.32085
  • Fairfax, Virginia, United States|38.84622,-77.30637

Key Eligibility Criteria

  • Measurable disease at baseline per RECIST v1.1
  • ECOG performance status of 0 or 1
  • Adequate organ function
  • Metastatic NSCLC:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →